BioMark has recently completed a very encouraging metabolome study that has implication for biomarker signature related to cancer diagnosis. The discovery is being patented.
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
Next-generation metabolomics and AI technology supports the 2026 – 2035 Pan-Canadian Lung Cancer Action Plan’s
Form 7 Monthly Progress Report September 2025 Name of Listed Issuer: Trading Symbol: Number of
BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial Extensive Validation of
Form 7 Monthly Progress Report September 2025 Name of Listed Issuer: Trading Symbol: Number of
BioMark Secures Key Patents in Asia’s Largest Markets for Early Lung Cancer Liquid Biopsy Pioneering
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2